A believer in Teva Pharmaceutical's (NYSE:TEVA) turnaround plan, Jana Partners has built a stake in the company, believing the stock to be worth $30 (50% upside), according to an investor letter.
Down earlier following a trial failure, Teva is ahead 1% in mid-morning action.
Now read: Teva: Et Tu, Moody's? »
Subscribe for full text news in your inbox